A Phase I, Randomized, Dose-Ranging, Pharmacokinetic, Glucodynamic, Safety, and Tolerability Study of SC Administered Humulin R and Humalog With or Without Recombinant Human Hyaluronidase (rHuPH20) in Healthy Volunteers.

Trial Profile

A Phase I, Randomized, Dose-Ranging, Pharmacokinetic, Glucodynamic, Safety, and Tolerability Study of SC Administered Humulin R and Humalog With or Without Recombinant Human Hyaluronidase (rHuPH20) in Healthy Volunteers.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2012

At a glance

  • Drugs Hyaluronidase; Insulin; Insulin lispro
  • Indications Diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 30 May 2012 Planned end date changed from 1 Dec 2009 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 11 Dec 2009 Planned end date changed from 1 Oct 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 29 Sep 2009 Results will be presented at the 2009 International Diabetes Federation Congress and the Diabetes Technology Society meeting according to a Halozyme Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top